Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. 
In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies.
In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes.
We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. 
Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.


Biotechnology

Life Sciences

Pharmaceutical

Meddenovo Drug Design

Meddenovo Drug Design's headquarters in Lyon, France

Description

People (1)

Ilke Ugur Marion

Jobs